145 related articles for article (PubMed ID: 2803975)
1. Circulating erythropoietin in patients with myelodysplastic syndromes.
Jacobs A; Janowska-Wieczorek A; Caro J; Bowen DT; Lewis T
Br J Haematol; 1989 Sep; 73(1):36-9. PubMed ID: 2803975
[TBL] [Abstract][Full Text] [Related]
2. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
Bowen DT; Jacobs A; Cotes PM; Lewis TC
Eur J Haematol; 1990 Jan; 44(1):30-2. PubMed ID: 2307217
[TBL] [Abstract][Full Text] [Related]
3. Marked erythropoietin-induced dysplastic erythropoiesis in a patient with myelodysplastic syndrome.
Narukawa K; Masuda A; Takahashi T
Int J Hematol; 2021 Jun; 113(6):775-776. PubMed ID: 33864622
[No Abstract] [Full Text] [Related]
4. Serum erythropoietin concentrations in patients with myelodysplastic syndromes.
Aul C; Arning M; Runde V; Schneider W
Leuk Res; 1991; 15(7):571-5. PubMed ID: 1861540
[TBL] [Abstract][Full Text] [Related]
5. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
7. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
8. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
10. Serum erythropoietin and reticulocyte counts in inflammatory process.
Souweine B; Serre AF; Philippe P; Conio N; Aumaitre O; Marcheix JC
Ann Med Interne (Paris); 1995; 146(1):8-12. PubMed ID: 7741403
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.
Boyko O; Simonova M; Knysh N; Danysh O; Vygovska Y; Masliak Z
Exp Oncol; 2021 Mar; 43(1):41-45. PubMed ID: 33785713
[TBL] [Abstract][Full Text] [Related]
12. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
14. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin.
Bowen D; Culligan D; Jacobs A
Br J Haematol; 1991 Mar; 77(3):419-23. PubMed ID: 2012769
[TBL] [Abstract][Full Text] [Related]
15. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
Bowen DT; Culligan D; Beguin Y; Kendall R; Willis N
Leukemia; 1994 Jan; 8(1):151-5. PubMed ID: 8289479
[TBL] [Abstract][Full Text] [Related]
16. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
17. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
18. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
Nakazaki K; Nannya Y; Kurokawa M
Int J Hematol; 2014 Jan; 99(1):53-6. PubMed ID: 24307517
[TBL] [Abstract][Full Text] [Related]
19. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
Qiao ZH
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]